AIM:SCLP

Stock Analysis Report

Executive Summary

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has Scancell Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.3%

SCLP

0.2%

GB Biotechs

-0.4%

GB Market


1 Year Return

-40.5%

SCLP

26.9%

GB Biotechs

2.9%

GB Market

Return vs Industry: SCLP underperformed the UK Biotechs industry which returned 26.9% over the past year.

Return vs Market: SCLP underperformed the UK Market which returned 2.9% over the past year.


Shareholder returns

SCLPIndustryMarket
7 Day-8.3%0.2%-0.4%
30 Day-13.5%2.9%-1.4%
90 Day-32.6%2.1%-2.1%
1 Year-40.5%-40.5%27.8%26.9%7.9%2.9%
3 Year-60.0%-60.0%12.3%10.3%18.0%3.6%
5 Year-83.7%-83.7%55.3%51.6%35.8%6.4%

Price Volatility Vs. Market

How volatile is Scancell Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Scancell Holdings undervalued compared to its fair value and its price relative to the market?

2.53x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate SCLP's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate SCLP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: SCLP is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: SCLP is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate SCLP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SCLP is overvalued based on its PB Ratio (2.5x) compared to the GB Biotechs industry average (2x).


Next Steps

Future Growth

How is Scancell Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

3.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SCLP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SCLP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SCLP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if SCLP's revenue is forecast to grow faster than the UK market.

High Growth Revenue: Insufficient data to determine if SCLP's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if SCLP's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Scancell Holdings performed over the past 5 years?

-20.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: SCLP is unprofitable, and losses have increased over the past 5 years at a rate of -20.8% per year.

Accelerating Growth: Unable to compare SCLP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SCLP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: SCLP has a negative Return on Equity (-60.27%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: SCLP is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: SCLP is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Scancell Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: SCLP's short term assets (£7.1M) exceeds its short term liabilities (£1.2M)

Long Term Liabilities: SCLP has no long term liabilities


Debt to Equity History and Analysis

Debt Level: SCLP is debt free.

Reducing Debt: SCLP has not had any debt for past 5 years.


Balance Sheet

Inventory Level: SCLP has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if SCLP's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: SCLP has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: SCLP has less than a year of cash runway if free cash flow continues to reduce at historical rates of -30.7% each year


Next Steps

Dividend

What is Scancell Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage0.8%forecastin3Years0%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate SCLP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate SCLP's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if SCLP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SCLP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SCLP's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Scancell Holdings's salary, the management and board of directors tenure and is there insider trading?

1.8yrs

Average management tenure


CEO

Cliff Holloway 0

1.8yrs

Tenure

UK£250,000

Compensation

Dr. Clifford Holloway, also known as Cliff, BPharm, Ph.D., is the Chief Executive Officer of Scancell Holdings Plc since January 10, 2018 and also serves as its Director. Dr. Holloway was the Chief Busines ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Cliff's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Cliff's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

1.8yrs

Average Tenure

Experienced Management: SCLP's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.


Board Age and Tenure

11.5yrs

Average Tenure

59yo

Average Age

Experienced Board: SCLP's board of directors are seasoned and experienced ( 11.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Lindy Durrant

    Chief Scientific Officer & Director

    • Tenure: 11.5yrs
    • Compensation: UK£175.00k
  • Cliff Holloway

    CEO & Director

    • Tenure: 1.8yrs
    • Compensation: UK£250.00k
  • Sally Adams (58yo)

    Development Director & Director

    • Tenure: 0yrs
    • Compensation: UK£193.13k
  • Keith Green

    Director of Finance & Administration

    • Tenure: 3.1yrs
  • Samantha Paston

    Head of Research

    • Tenure: 0.8yrs
  • Adrian Parry

    Head of Manufacturing

    • Tenure: 0.7yrs

Board Members

  • Matthew Gerard Frohn

    Non-Executive Director

    • Tenure: 11.5yrs
    • Compensation: UK£25.00k
  • Lindy Durrant

    Chief Scientific Officer & Director

    • Tenure: 11.5yrs
    • Compensation: UK£175.00k
  • Richard Goodfellow

    Director

    • Tenure: 11.5yrs
    • Compensation: UK£145.83k
  • John Chiplin (60yo)

    Non-Executive Chairman

    • Tenure: 3.8yrs
    • Compensation: UK£50.00k
  • Alan Lewis (73yo)

    Senior Independent Director

    • Tenure: 0yrs
    • Compensation: UK£25.83k
  • Cliff Holloway

    CEO & Director

    • Tenure: 1.8yrs
    • Compensation: UK£250.00k
  • Martin Diggle (56yo)

    Non-Executive Director

    • Tenure: 0.3yrs
  • Sally Adams (58yo)

    Development Director & Director

    • Tenure: 0yrs
    • Compensation: UK£193.13k

Company Information

Scancell Holdings plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Scancell Holdings plc
  • Ticker: SCLP
  • Exchange: AIM
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£28.387m
  • Shares outstanding: 465.36m
  • Website: https://www.scancell.co.uk

Number of Employees


Location

  • Scancell Holdings plc
  • John Eccles House
  • Robert Robinson Avenue
  • Oxford
  • Oxfordshire
  • OX4 4GP
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SCLPAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPSep 2008
SCNL.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDSep 2008
SCPDB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2008

Biography

Scancell Holdings plc engages in the discovery and development of novel vaccines for the treatment of various cancers. The company’s product candidates include SCIB1, which completed phase II clinical tria ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/19 21:36
End of Day Share Price2019/10/18 00:00
Earnings2019/04/30
Annual Earnings2019/04/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.